Skip to content

Ovarian Cancer Reference

Ovarian cancer is an umbrella term for several malignancies involving the ovaries. Epithelial ovarian cancer is managed together with closely related fallopian-tube and primary peritoneal cancers because they share biology, patterns of spread, staging, and treatment. Many tumors historically labeled ovarian high-grade serous carcinoma are now understood to arise from precursor lesions in the fimbrial end of a fallopian tube.

High-grade serous ovarian carcinoma is the most common aggressive epithelial form, but it is not interchangeable with every ovarian cancer. Low-grade serous, endometrioid, clear-cell, mucinous, germ-cell, and sex-cord stromal tumors differ in biology, age distribution, treatment, and course.

Signs and Presentation

Ovarian, fallopian-tube, and primary peritoneal cancers may produce persistent but nonspecific symptoms. Common presentations include abdominal or pelvic pain, pressure or swelling; bloating; feeling full quickly; difficulty eating; urinary urgency or frequency; constipation or other bowel changes; abnormal vaginal bleeding; fatigue; and unexplained weight change. Ascites can enlarge the abdomen, worsen early fullness, and cause shortness of breath.

These symptoms are common in benign conditions. Their persistence, change from a person’s baseline, clustering, or progression can prompt further evaluation, but no individual symptom proves cancer. Some people have few noticeable symptoms until disease is advanced.

The older label ‘’silent killer’’ obscures this variability. Symptoms can exist before diagnosis without being specific enough to identify ovarian cancer on their own. Delayed recognition may involve self-attribution, limited access to care, fragmented evaluation, clinician dismissal, or an initially reasonable benign explanation that is not revisited when symptoms persist.

Risk and Genetics

Risk increases with age and with some family histories and inherited cancer-predisposition syndromes. Pathogenic germline variants in BRCA1 or BRCA2 substantially increase ovarian and breast cancer risk. Lynch syndrome and pathogenic variants in several other genes can also increase risk.

A BRCA result requires precision. A pathogenic or likely pathogenic variant can affect treatment and relatives’ risk assessment; a variant of uncertain significance does not carry the same meaning. A tumor BRCA change may be inherited or confined to the tumor. Genetic counseling and germline testing distinguish those possibilities.

Current guidance recommends germline testing for people diagnosed with epithelial ovarian cancer and tumor testing when indicated. If a germline pathogenic variant is found, adult blood relatives can receive individualized counseling and decide whether to pursue testing. The finding does not establish that every relative carries the variant or will develop cancer.

BRCA-associated breast and ovarian cancers are related through inherited susceptibility, but one does not transform into the other. Triple-negative breast cancer is a separate breast-cancer diagnosis defined by absence of estrogen receptor, progesterone receptor, and HER2 expression. It is more strongly associated with BRCA1 than with BRCA2, although triple-negative disease does not itself prove a BRCA variant.

Screening, Evaluation, and Diagnosis

No population screening test has been shown to reduce ovarian-cancer mortality among people at average risk. Transvaginal ultrasound and CA-125 testing can contribute to the evaluation of symptoms or an adnexal mass, but neither is sufficiently accurate as a stand-alone screening or diagnostic test. CA-125 may be normal in some cancers and elevated in benign conditions or other malignancies.

Evaluation can include history, physical and pelvic examination, ultrasound, CT or other imaging, blood tests, and referral to gynecologic oncology. Imaging estimates extent and guides planning; pathological examination establishes the tumor type. Surgery provides definitive staging in many patients without extra-abdominal metastatic disease. Molecular and germline testing guide hereditary-risk counseling and selected treatment decisions.

Persistent gastrointestinal, urinary, abdominal, or bleeding symptoms require a differential diagnosis. Benign ovarian cysts, endometriosis, uterine disease, gastrointestinal disorders, urinary disorders, pregnancy-related conditions, and other cancers can overlap with the presentation. Evaluation should pursue the cause without treating anxiety, caregiving demands, age, body size, race, or gender identity as an explanation for persistent physical change.

Grade, Stage, and Recurrence

‘’Grade’’ describes how abnormal and aggressive tumor cells appear. ‘’Stage’’ describes the disease’s anatomical extent at diagnosis. High-grade serous carcinoma is a histological diagnosis; Stage IIIC and Stage IV are anatomical classifications.

FIGO Stage III disease has spread outside the pelvis to the peritoneum and/or retroperitoneal lymph nodes. Stage IIIC includes macroscopic extrapelvic peritoneal metastases larger than two centimeters, with or without retroperitoneal lymph-node involvement; spread to the capsule of the liver or spleen remains Stage III. Stage IV requires distant metastasis outside the peritoneal cavity, including malignant pleural fluid or metastasis within organs such as the liver or spleen.

A person’s original stage remains part of the diagnosis even if the cancer later recurs. Later disease may be described as recurrent, persistent, platinum-sensitive or platinum-resistant in a treatment context, or distant metastatic disease. A recurrence does not change high-grade serous carcinoma into a higher histological grade.

Treatment

Treatment depends on histology, stage, resectability, molecular findings, prior therapy, response, toxicity, other health conditions, and the patient’s goals. Care is commonly coordinated by a gynecologic oncologist and a multidisciplinary team.

Surgery and Initial Systemic Treatment

For advanced epithelial disease, treatment commonly combines cytoreductive surgery with platinum-based chemotherapy. Some patients undergo primary surgery followed by chemotherapy. Others receive neoadjuvant chemotherapy first and then interval cytoreductive surgery when that sequence offers a safer or more effective route. Surgery may include removal of the uterus, ovaries, fallopian tubes, omentum, and other involved tissue, but the procedure is individualized to disease extent and operative risk.

Carboplatin with paclitaxel is a longstanding first-line combination for advanced high-grade serous disease. Bevacizumab may be added in selected situations. Antiemetics, hydration, blood-count monitoring, infection management, nutrition support, pain treatment, and rehabilitation are part of cancer care rather than optional additions to it.

Biomarker-Directed and Maintenance Therapy

PARP inhibitors can be used in selected maintenance settings, particularly when a tumor has a BRCA pathogenic variant or homologous-recombination deficiency and has responded to platinum treatment. Eligibility differs by drug, biomarker, treatment line, prior response, toxicity, and current regulatory labeling. A BRCA result does not make every PARP inhibitor appropriate at every point in the disease.

Maintenance therapy aims to prolong control after a response; it is not evidence that the cancer has been eradicated. Surveillance can include symptom review, examination, imaging when indicated, and CA-125 when clinically useful. Rising CA-125 alone does not describe the full clinical state or automatically determine treatment.

Recurrent or Persistent Disease

Recurrence is common after advanced epithelial ovarian cancer, but timing and course vary. Treatment may include another platinum-based regimen, non-platinum chemotherapy, bevacizumab, biomarker-directed therapy, selected surgery, a clinical trial, or symptom-directed care. Prior response, interval since platinum exposure, cumulative neuropathy or marrow toxicity, kidney function, other conditions, and patient priorities shape the next line of treatment.

Palliative care can begin alongside disease-directed treatment. It addresses pain, nausea, fatigue, appetite, sleep, emotional distress, communication, family needs, and care planning. Hospice is distinct from palliative care and is considered when disease-directed control is no longer the goal.

Treatment Effects and Access

Cancer and treatment affect people differently. Platinum and taxane chemotherapy can cause fatigue, nausea and vomiting, mouth or throat sores, hair loss, neuropathy, altered taste, anemia, low neutrophil counts, infection risk, and other toxicities. Antiemetics prevent or reduce vomiting for many people, but some still experience severe symptoms. Blood-count changes and infection precautions are guided by the individual regimen, laboratory results, and oncology team rather than one universal household protocol.

Cytoreductive surgery can require substantial recovery and may cause surgical menopause and infertility when both ovaries are removed. Abdominal pain, bowel changes, weakness, early fullness, and mobility limits can arise from the cancer, ascites, surgery, medication, deconditioning, or several causes at once. Long-term effects can include fatigue, neuropathy, fear of recurrence, altered body image, and practical changes in work, parenting, sex, and household roles.

Access needs may include step-free clinics, adjustable examination and imaging equipment, transfer assistance, interpretation, plain-language or AAC-compatible explanations, medication formats that remain usable during nausea or mucositis, quiet waiting space, rest breaks, transport, home support, and flexible scheduling around treatment and recovery. Most people diagnosed are women, but transgender men and nonbinary people with relevant anatomy can also develop these cancers and may face additional barriers to gynecologic care.

Family and community support can provide meals, transport, childcare, medication pickup, infection-conscious visits, fundraising, and respite. Support does not replace professional home health, symptom management, or the patient’s authority over who receives medical information and who enters the home.

Medical-System Context

Nonspecific symptoms can be missed when each complaint is evaluated in isolation or when a benign explanation is not revisited. Racial inequity, insurance and transport barriers, fragmented specialty care, inaccessible equipment, weight bias, and gendered assumptions about pain or caregiving can delay evaluation and treatment. The presence of disparity does not prove that every delayed diagnosis resulted from intentional dismissal; the clinical record, repeated contacts, follow-up, and access history matter.

Ovarian-cancer language can also become fatalistic. Population survival figures do not predict one person’s remaining time, and remission, response, stable disease, recurrence, and cure are not interchangeable. Disease-directed treatment can coexist with rehabilitation and palliative care, while a decision to stop a treatment can reflect toxicity, lack of benefit, or a person’s goals rather than surrender.

History

Twentieth-century treatment moved from alkylating-agent regimens toward platinum chemotherapy, followed by platinum-taxane combinations and improved cytoreductive surgery. Molecular pathology later clarified that many high-grade serous tumors arise in the fallopian tube and that ovarian, fallopian-tube, and primary peritoneal cancers often belong to one clinical disease group. BRCA and homologous-recombination testing introduced biomarker-directed maintenance options while also changing hereditary-risk counseling.

These advances did not create an effective average-risk screening program. Symptom-responsive evaluation, access to gynecologic oncology, accurate pathology, molecular testing, supportive care, and equitable treatment remain central to outcomes.

Marisa Garcia

Marisa Garcia was diagnosed in August 2039 with Stage IIIC high-grade serous ovarian carcinoma at age forty, when Mateo Garcia was nearly twelve. In the preceding months, she experienced persistent bloating, deep fatigue, and irregular bleeding. She attributed the changes to stress and the demands of caring for Mateo until the symptoms overlapped and progressed.

Marisa’s initial treatment included platinum-and-taxane chemotherapy and cytoreductive surgery. Her first chemotherapy cycle caused severe nausea and vomiting, painful mouth and throat ulcers, rapid weight loss, skin sensitivity, port discomfort, and profound fatigue. Luis Garcia, Ana, Rosario, the Medical Mom Squad, and the school community redistributed household work and caregiving. Marisa and Luis temporarily sent Mateo to Baltimore to stay with Jess Ross and Noah Donelly during the most acute period; he returned when the distress of separation outweighed the benefit of remaining away.

After the initial treatment phase, Marisa entered a period of remission or clinical stability. Noah waited for that stronger window before asking her blessing and help planning his proposal to Jess in 2039. Her energy remained limited, but the planning and engagement call brought sustained joy back into the Garcia household.

During Marisa’s cancer care, testing identified a pathogenic BRCA variant. When Mateo was fourteen, she served as matron of honor at Jess and Noah’s Baltimore wedding. Her ovarian cancer later recurred with distant metastatic disease, and she was also treated for triple-negative breast cancer. The cancers and cumulative treatment burden left her increasingly weak, sleeping much of the day, eating little, and relying on Ana, Luis, and the wider support network for household and caregiving work.

Marisa died in 2042 after several years of treatment for both metastatic ovarian cancer and triple-negative breast cancer.

Sources

  • [https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq National Cancer Institute: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment—Health Professional Version]
  • [https://www.cancer.gov/types/ovarian/patient/ovarian-epithelial-treatment-pdq National Cancer Institute: Treatment of Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers]
  • [https://www.cancer.gov/types/ovarian/hp/ovarian-screening-pdq National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Screening—Health Professional Version]
  • [https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet National Cancer Institute: BRCA Gene Changes—Cancer Risk and Genetic Testing]
  • [https://pubmed.ncbi.nlm.nih.gov/31986064/ American Society of Clinical Oncology: Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer]
  • [https://www.cancer.gov/about-cancer/treatment/side-effects National Cancer Institute: Side Effects of Cancer Treatment]
  • [https://www.cancer.gov/about-cancer/advanced-cancer/care-choices/palliative-care-fact-sheet National Cancer Institute: Palliative Care in Cancer]
Medical Conditions Oncology Marisa Garcia